Form 4 Kura Oncology Inc: Brian T. Powl (Chief Commercial Officer) For: 19 November By Investing.com
This article reports on a Form 4 filing for Kura Oncology Inc, detailing insider transactions by Brian T. Powl, the Chief Commercial Officer, for November 19. The filing indicates a significant event related to insider activity within the company.
After selling 448 shares, Brian T. Powl held 112,817 Kura Oncology (KURA) shares directly.
Brian T. Powl, Chief Commercial Officer of Kura Oncology, sold 448 shares of common stock at $7.27 per share on November 19, 2026, under a Rule 10b5-1 trading plan. Following the transaction, his direct holdings in KURA amounted to 112,817 shares. The filing of this insider trading activity on an SEC Form 4 indicates a neutral sentiment and impact on the stock.
Kura Oncology (KURA) commercial chief Brian T. Powl sold 24,450 shares, some to cover taxes.
Kura Oncology's Chief Commercial Officer, Brian T. Powl, reported direct sales of 24,450 common shares on November 16 and 17, 2026. A portion of these sales, 9,196 shares, was specifically to cover taxes related to the vesting of restricted stock units. The remaining 15,254 shares were sold under a pre-adopted Rule 10b5-1 trading plan.
A planned sale of 8,601 Kura Oncology (KURA) shares covered taxes from a stock award vesting.
Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, sold 8,601 shares of common stock at $7.44 per share on November 16, 2026. This transaction, executed under a Rule 10b5-1 trading plan, was a "sell-to-cover" sale to pay taxes associated with the vesting of performance-based restricted stock units. After the sale, Ms. Bair directly held 178,401 shares of Kura Oncology.
Chairman of Kura Oncology Picks Up 16% More Stock
Kura Oncology's Chairman, Troy Wilson, recently purchased US$1.5m worth of stock at US$7.52 per share, increasing his holding by 16%. This significant insider buying activity, combined with other past purchases, suggests that insiders believe the company's share price might be undervalued, despite the company having made a loss in the last year. Insider ownership stands at 1.5% of the company, valued at approximately US$10m.
Kura Oncology Officer Kathleen Ford Announces Intent to Sell 3,668 Shares Under Rule 144
Kura Oncology officer Kathleen Ford has filed a Form 144 indicating her intent to sell 3,668 shares of common stock, valued at approximately $26,006.12. These shares were acquired through Performance Stock Units on November 13, 2026, and the sale is expected to occur on November 17, 2026, as part of a Rule 10b5-1 trading plan adopted earlier in the year. Ford has also made several other share sales in the preceding three months, totaling 17,616 shares.
Is Kura Oncology (NASDAQ:KURA) Presenting at UBS and Jefferies?
Kura Oncology (NASDAQ:KURA) announced its management will present at the UBS Global Biopharma London Conference and the Jefferies Global Healthcare Conference in mid-November. The biopharmaceutical company recently reported strong commercial performance for its FDA-approved oral menin inhibitor, KOMZIFTI, in its latest-quarter update. Live audio webcasts of the presentations will be available on the company's website, with archived replays posted afterwards.
Kura Oncology CEO Troy Wilson buys $1.5M in shares
Kura Oncology CEO Troy Wilson recently purchased over $1.5 million worth of company shares, acquiring 200,000 shares across two transactions in November 2026. These purchases occurred as the stock traded near its 52-week low, with shares down approximately 32% year-to-date, and InvestingPro analysis suggesting the company is undervalued. Following these acquisitions, Wilson's direct and indirect holdings in Kura Oncology increased significantly.
Kura Oncology (KURA) CEO Wilson bought 200,000 shares for $1.5M at an average $7.52
Kura Oncology (KURA) CEO Troy Edward Wilson purchased 200,000 shares of the company's stock for $1.5 million at an average price of $7.52 per share between November 13 and November 16, 2026. This transaction increased his direct stake by 46% to 635,456 shares. The report details the specific dates and prices of the open-market purchases and provides an overview of his holdings before and after these transactions.
CEO Troy Edward Wilson makes two November share purchases in Kura Oncology (KURA).
Kura Oncology's President and CEO, Troy Edward Wilson, made two direct purchases of the company's common stock in November 2026. He acquired 98,881 shares at a weighted average price of $7.63 on November 13 and an additional 101,119 shares at $7.42 on November 16. These transactions, totaling 200,000 shares, increased his direct position by 45.9% and were reported in detail through an SEC Form 4 filing.
Kura Oncology: JNJ's Bleximenib Is A Serious Threat, But Kura Still Has A Fighting Chance
Kura Oncology faces a serious threat from Johnson & Johnson's bleximenib, which has shown stronger efficacy metrics, leading to a recent 25% drop in KURA's stock value. Despite this, Kura Oncology maintains a "cautious Hold" rating, with its lower hematologic toxicity potentially favoring chemotherapy combinations, and upcoming ASH updates and KOMET-017 Phase 3 results in 2028 offering key milestones. The company's $6.75 valuation implies a roughly 10% downside, balanced by its established market presence and potential for combination therapies.
How Kura Oncology Inc. (KURA) Affects Rotational Strategy Timing
This article provides an analysis of Kura Oncology Inc. (KURA) for rotational trading strategies, detailing three distinct AI-generated trading plans: Position Trading (Long), Momentum Breakout (Breakout), and Risk Hedging (Short). It highlights divergent sentiment readings, suggesting choppy market conditions, and identifies specific entry, target, and stop-loss levels for each strategy. The analysis also includes multi-timeframe signal analysis, outlining support and resistance levels across near, mid, and long-term horizons.
Two Kura Oncology presentations will stream live, with replays available afterward.
Kura Oncology (KURA) announced that its management will present at two investor conferences in November 2026. The presentations will occur at the UBS Global Biopharma London Conference on November 17th and the Jefferies Global Healthcare Conference on November 18th. Live audio webcasts and archived replays will be accessible through Kura's investor website.
Kura Oncology to Participate in Two Investor Conferences in November
Kura Oncology, Inc. announced its participation in two investor conferences in November: the UBS Global Biopharma London Conference on November 17, 2026, and the Jefferies Global Healthcare Conference on November 18, 2026. Management will present at these events, with live audio webcasts and archived replays available on the company's website. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, developing and commercializing KOMZIFTI® (ziftomenib) for acute myeloid leukemia.
Kura Oncology to Participate in Two Investor Conferences in November
Kura Oncology, Inc. announced its participation in two investor conferences in November 2026. Management will present at the UBS Global Biopharma London Conference and the Jefferies Global Healthcare Conference to discuss the company's focus on precision medicines for cancer treatment. Live audio webcasts and archived replays will be available on Kura Oncology's website.
Kura Oncology, Inc. (NASDAQ:KURA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Kura Oncology, Inc. (NASDAQ:KURA) recently released its third-quarter results, showing a 9.3% rise in shares despite revenues coming in 4.4% below estimates. Analysts have updated their forecasts, now expecting revenues of US$199.0m in 2027, a 151% improvement, but also an increase in projected losses. The consensus price target remains unchanged at US$31.85, suggesting that the weaker earnings outlook may not impact long-term valuation.
Kura Oncology Q3 2026 slides: KOMZIFTI revenue surges 53% sequentially
Kura Oncology reported strong Q3 2026 financial results, with KOMZIFTI net product revenue surging 53% sequentially to $13.9 million, driven by increased new patient starts and total prescriptions. The company also announced FDA alignment on a registrational path for its second precision medicine candidate, darlifarnib, and highlighted a robust financial position to support commercial execution and pipeline advancement. Despite missing total revenue estimates, Kura beat adjusted loss per share expectations, and its shares rose significantly.
Kura Oncology Inc (KURA) (Q3 2026) Earnings Call Highlights: KOMZIFTI Revenue Surges 53% as ...
Kura Oncology reported a significant 53% sequential surge in KOMZIFTI net product revenue to $13.9 million in Q3 2026, driven by a 30% increase in new patient starts and 65% rise in total prescriptions. The company also secured up to $300 million in financing from Oberland Capital, strengthening its financial position, despite a decrease in collaboration revenue and a net loss of $70.2 million for the quarter. Kura Oncology maintains leadership in menin inhibitor new patient starts and plans for upcoming ASH presentations and a registrational study for darlifarnib.
Form S-3ASR Kura Oncology Inc For: 10 November By Investing.com
This article announces the filing of Form S-3ASR by Kura Oncology Inc. on November 10. The content itself is very brief, serving primarily as a notification of the regulatory filing and offering access to Investing.com's market data. The article also provides a current stock price and highlights related market trends.
Kura Oncology Releases Q3 2026 Financial Results
Kura Oncology, Inc. (KURA) reported its Q3 2026 financial results, beating analyst expectations with a narrower loss of $0.78 per share against an anticipated $0.81 loss. Despite a 4.4% revenue miss at $22.8M compared to estimates, the company saw a 10.1% increase in revenue year-over-year, alongside 150 new patient starts. Analyst sentiment remains largely positive, with a consensus of 13 buy ratings.
Kura Oncology Inc earnings beat by $0.03, revenue fell short of estimates
Kura Oncology Inc reported third-quarter earnings per share (EPS) of $-0.780, beating analyst estimates by $0.03. However, the company's revenue of $22.83M fell short of the consensus estimate of $24.86M. Kura Oncology Inc's stock has seen a significant decline over the last 3 and 12 months, and its financial health is rated as "weak performance."
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
Kura Oncology announced strong third-quarter 2026 financial results, with KOMZIFTI net product revenue growing 53% sequentially to $13.9 million, driven by a 30% increase in new patient starts. The company also reached FDA alignment for a registrational study of darlifarnib in HRAS-mutated salivary gland cancer, targeting initiation in the first half of 2027. Kura Oncology secured up to $300 million in additional financing capacity and reported a strengthened cash position of $492.1 million.
Revenue rose to $22.8M at Kura Oncology (KURA), but Q3 still ended in a loss.
Kura Oncology reported third-quarter 2026 revenue of $22.839 million, an increase from $20.750 million a year earlier, primarily driven by $13.922 million in KOMZIFTI product revenue. Despite the revenue growth, the company recorded a net loss of $70.215 million, which was narrower than the $74.116 million loss reported in the prior year. Kura Oncology continues to advance its clinical development programs for ziftomenib and darlifarnib, and recently secured $50.0 million in new loan funding and an additional $5.0 million equity investment, with capacity for up to $225.0 million in further borrowing.
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
Kura Oncology announced strong third quarter 2026 financial results, with KOMZIFTI net product revenue growing 53% sequentially to $13.9 million. The company also reported FDA alignment for a registrational study of darlifarnib in HRAS-mutated salivary gland cancer, targeting initiation in the first half of 2027. Kura Oncology strengthened its financial position with a new strategic financing agreement providing up to $300 million and maintained its collaboration revenue guidance for 2026, 2027, and 2028.
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
Kura Oncology reported strong third-quarter 2026 financial results, with KOMZIFTI net product revenue growing 53% sequentially to $13.9 million, driven by a 30% increase in new patient starts. The company also announced FDA alignment for a registrational study of darlifarnib in HRAS-mutated salivary gland cancer and secured up to $300 million in additional financing. Kura Oncology's financial position remains strong, with $492.1 million in cash, cash equivalents, and short-term investments, and anticipates continued investment in its precision oncology franchises.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards of nonstatutory stock options to three new employees. These awards, covering 55,500 shares of common stock, were approved in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. The options have an exercise price of $9.79 per share and will vest over four years.
Three new hires receive rights to buy Kura shares at $9.79 each, phased in over four years.
Kura Oncology granted stock options for 55,500 shares to three new employees on November 2, 2026, with an exercise price of $9.79 per share, matching the closing price on the grant date. These inducement awards, approved under Nasdaq Listing Rule 5635(c)(4), will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over 36 months, subject to continued employment. This move aims to incentivize new hires while potentially leading to minor share dilution.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards of nonstatutory stock options to three new employees on November 2, 2026. These awards, totaling 55,500 shares, were approved under the Company’s 2023 Inducement Option Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $9.79 per share and will vest over four years, contingent on continued employment.
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
Kura Oncology and Kyowa Kirin announced that eight abstracts related to ziftomenib, including four oral presentations and four posters, have been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting. The presentations will feature the first clinical results for ziftomenib in combination with FLT3 inhibitors quizartinib and gilteritinib, longer-term frontline data, and an exploratory analysis of ziftomenib activity in various AML subtypes. This aims to establish ziftomenib as a preferred menin inhibitor for combination treatment across AML treatment settings.
(KURA) Volatility Zones as Tactical Triggers
This article provides an AI-generated analysis of Kura Oncology Inc. (NASDAQ: KURA), identifying neutral near and mid-term readings but a strong long-term positive bias. It offers three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Kura Oncology to Report Third Quarter Financial Results on November 10
Kura Oncology, Inc. announced it will report its third-quarter 2026 financial results on Tuesday, November 10, 2026, after market close. Following the report, Kura’s management will host a webcast and conference call to discuss the results and provide a corporate update. The company, focused on precision medicines for cancer, has developed and commercialized KOMZIFTI® (ziftomenib) and is advancing other small molecule drug candidates.
Kura Oncology to Report Third Quarter Financial Results on November 10
Kura Oncology (Nasdaq: KURA) announced it will report its third-quarter 2026 financial results after market close on Tuesday, November 10, 2026. The company's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, developing therapies like KOMZIFTI® (ziftomenib) for acute myeloid leukemia.
Kura Oncology to Report Third Quarter Financial Results on November 10
Kura Oncology, Inc. announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, and is commercializing KOMZIFTI® (ziftomenib) for NPM1-mutated acute myeloid leukemia.
Kura Oncology to Report Third Quarter Financial Results on November 10
Kura Oncology, Inc. announced it will release its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, commercializing KOMZIFTI® (ziftomenib).
Kura Oncology to Report Third Quarter Financial Results on November 10
Kura Oncology, Inc. (Nasdaq: KURA) announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. The company's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, developing and commercializing KOMZIFTI® (ziftomenib).
Kura Oncology to Report Third Quarter Financial Results on November 10
Kura Oncology, Inc. announced it will report its third-quarter 2026 financial results after market close on Tuesday, November 10, 2026. Following the release, management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, commercializing KOMZIFTI® (ziftomenib) for NPM1-mutated acute myeloid leukemia.
Kura Oncology Inc (KUR.SG) Seasonal returns chart - Yahoo Finance
The article displays a seasonal returns chart for Kura Oncology Inc (KUR.SG) on Yahoo Finance. It shows the average monthly price return for the stock from 2017 to 2026. The page also provides current market data for various global indices and cryptocurrencies.
Kura Oncology, Inc. (KURA) Options Chain
This article provides the options chain for Kura Oncology, Inc. (KURA), showing its stock price and options data. As of the data presented, there were no calls or puts available for the company. The information indicates a market open status with data delayed by 15 minutes.
Kura Oncology, Inc. (KURA) Seasonal returns chart
This article provides a seasonal returns chart for Kura Oncology, Inc. (KURA), showing the average monthly price return from 2016 to 2026. The stock's current price is listed at $10.26, reflecting a slight decline at market close on October 30.
UBS Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $15
UBS has reiterated its Buy rating for Kura Oncology (KURA.US) and maintained its target price at $15. This indicates a continued positive outlook from the firm regarding Kura Oncology's stock performance.
BlackRock Reports 8.9% Ownership Stake in Kura Oncology as of September 2026
BlackRock, Inc. has reported an 8.9% beneficial ownership stake in Kura Oncology Inc. common stock as of September 30, 2026. This includes sole voting power over 7,763,592 shares and sole dispositive power over all 7,908,832 shares. The filing, Amendment No. 8 to Schedule 13G, indicates the securities were acquired and are held in the ordinary course of business, not to influence control of the issuer.
UBS keeps USD 15 target for Kura Oncology stock
UBS has maintained its USD 15.00 price target for Kura Oncology, reiterating a Buy rating on the stock. Kura Oncology reported USD 20.87 million in second-quarter 2026 revenue and is expected to release its third-quarter results on November 3, 2026, with analysts forecasting increased revenue but continued losses. The stock's performance and upcoming results will be crucial in assessing its commercial execution and cash utilization.
Form 144 KURA ONCOLOGY For: 25 October By Investing.com
This article from Investing.com announces the filing of Form 144 for KURA Oncology on October 25, 2026. Form 144 is a notice of the intent to sell restricted stock. The article provides a brief mention of the company's stock performance (-2.54%) and was published on October 25, 2026, at 13:16.
Form 144 KURA ONCOLOGY For: 25 October By Investing.com
This article announces the filing of Form 144 for Kura Oncology (KURA) on October 25, 2026. Form 144 is a notice filed with the SEC by an affiliate of a company proposing to sell restricted securities. The article provides the title of the filing and mentions KURA's stock performance.
Kura Oncology, Inc. Estimates – NASDAQ:KURA
This article provides an overview of Kura Oncology, Inc. (NASDAQ: KURA) financial estimates on TradingView. It highlights where users can explore reported financial data and analyst estimates, including income statements, balance sheets, and cash flow statements. The platform allows for comparing actual results with average, high, and low estimates and visualizing trends over time.
Kura Oncology, Inc. Estimates – HAM:KUR
This article provides access to financial actuals and analyst estimates for Kura Oncology, Inc. (HAM:KUR) on the Hamburg Stock Exchange. Users can explore reported financial data and compare it with average, high, and low estimates across various financial statements and valuation metrics. The platform emphasizes that this information is not investment advice and encourages users to conduct their own research.
UBS reaffirms USD 15 target for Kura Oncology stock
UBS has reaffirmed its Buy rating and USD 15.00 price target for Kura Oncology (KURA) as of October 5, 2026, citing strong early commercial execution for Komzifti and favorable prescribing trends. Kura Oncology's second-quarter 2026 revenue of USD 20.87 million exceeded analyst expectations. The stock is currently trading below its 52-week high, and quarterly results are scheduled for November 3, 2026.
UBS keeps USD 15.00 target for Kura Oncology stock
UBS has reiterated a Buy rating and a USD 15.00 price target for Kura Oncology (KURA) stock. This target is 54.64% above the Nasdaq price of USD 9.70 as of October 15, 2026. The company reported Q2 2026 revenue of USD 20.87 million, exceeding expectations, and is scheduled to report earnings on November 3, 2026.
(KURA) and the Role of Price-Sensitive Allocations
This article analyzes Kura Oncology Inc. (NASDAQ: KURA), noting weak near and mid-term sentiment despite a positive long-term outlook. AI models have generated three trading strategies for different risk profiles, highlighting an exceptional 57.7:1 risk-reward setup. Key support and resistance levels are provided across various time horizons.
J.P. Morgan Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $30
J.P. Morgan has reiterated its Buy rating for Kura Oncology (KURA.US) and maintained its price target of $30. This suggests a continued positive outlook from the firm regarding the company's stock performance.